Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Vakov et al., 2023)
They argue that cities and states will then have to pay for more health problems related to obesity
In a 10-week, once-daily, multiple-dose trial, 84 healthy males received 20 or 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC, and 23 males with type 2 diabetes (T2D) received 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC
Absorption rate determines how quickly the injected dose enters the bloodstream
The SURMOUNT-1 trial: Those on tirzepatide GIP GLP-1 (Mounjaro) saw up to 20.9% reduction [2]
US$ 21.61
US$ 20.18
US$ 22.22
US$ 26.46
US$ 29.25
US$ 22.77
